KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NFzTepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTxTWM2OD1|LkK3N|UzKM7:TR?= NWrNcnJJW0GQR1XS
HuO-3N1 NWTOb|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\UVIpQUUN3ME20MlE4OTR{IN88US=> MYDTRW5ITVJ?
LAMA-84 M2LLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\IVmlEPTB;ND61PFQ3PSEQvF2= NFK0PYRUSU6JRWK=
CAL-72 NXPVbZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\JV2VKSzVyPUWuOFgxQDRizszN M{P0[HNCVkeHUh?=
LoVo NHHUeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDKTWM2OD14LkmzNlM6KM7:TR?= M37OPHNCVkeHUh?=
HH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPGTWM2OD16LkK3OlcyKM7:TR?= MUHTRW5ITVJ?
SK-MEL-3 NH\HVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDRTWM2OD16LkK4OVc2KM7:TR?= Mlj0V2FPT0WU
KM12 NW\rbFNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\jWmlEPTB;OT6yNVE1OiEQvF2= NV30emxPW0GQR1XS
NCI-H1437 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\nb5NrUUN3ME25MlgxQTdizszN MmDkV2FPT0WU
NCI-H1838 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojBTWM2OD1zMT6xPFY2KM7:TR?= NUi2VpRqW0GQR1XS
J-RT3-T3-5 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW4SJRXUUN3ME2xNU4zPDF5IN88US=> NVrUV|hoW0GQR1XS
GOTO Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj4PFlKSzVyPUGxMlY6QTZizszN MUnTRW5ITVJ?
LB2241-RCC MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFzLkexPFYh|ryP M1\SVnNCVkeHUh?=
ES7 NIqxb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFzLke4PEDPxE1? M3;Lb3NCVkeHUh?=
KP-N-YS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDMTWM2OD1zMj62N|U1KM7:TR?= MYTTRW5ITVJ?
CAL-12T MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF|Lk[xO{DPxE1? NVfDdpZ{W0GQR1XS
COLO-684 NFj2XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLFNGgyUUN3ME2xOE4yPTZ7IN88US=> MXrTRW5ITVJ?
DOK NVvGbXB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjrSXJpUUN3ME2xOU4{OzJ7IN88US=> MVzTRW5ITVJ?
Hs-578-T NVPhOlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\jSnhKUUN3ME2xOU41OTh{IN88US=> NXfQeYYzW0GQR1XS
D-423MG NFPP[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF3LkWyN|Yh|ryP MWLTRW5ITVJ?
DBTRG-05MG MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF3Lk[xNVEh|ryP NYDyPZFkW0GQR1XS
VM-CUB-1 NF\2dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DBWmlEPTB;MUWuPVg1QSEQvF2= NFrXWW9USU6JRWK=
KG-1 NVTseGlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S1O2lEPTB;MU[uNFk6PiEQvF2= M{XidnNCVkeHUh?=
8305C M3W5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnHcZAyUUN3ME2xOk4yQDh7IN88US=> MnG2V2FPT0WU
HuH-7 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq1RZhKSzVyPUG2MlI3PzRizszN MofJV2FPT0WU
LXF-289 M2DBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLmTWM2OD1zNj6yO|Q4KM7:TR?= Mni2V2FPT0WU
NCI-H1793 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H1UmlEPTB;MU[uOFcyOiEQvF2= MWTTRW5ITVJ?
ChaGo-K-1 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF4Lk[1Olgh|ryP NGDNN3dUSU6JRWK=
GCIY M{DsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF4Lke5NFUh|ryP M320fnNCVkeHUh?=
SK-MEL-28 M2LDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF5LkC0O|Uh|ryP MnTHV2FPT0WU
NCI-SNU-1 NWH5WopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTncohKSzVyPUG3MlEzPjlizszN MUTTRW5ITVJ?
CTB-1 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzsTWM2OD1zNz6yNlU6KM7:TR?= MY\TRW5ITVJ?
NCI-H82 NFHJXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnGTWM2OD1zNz60OVc{KM7:TR?= M{fsRXNCVkeHUh?=
HCC2998 NUTLOmVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF5Lk[3N|Mh|ryP MorTV2FPT0WU
NCI-H2030 M{PTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfhUZlKSzVyPUG4MlE6QTdizszN Moq1V2FPT0WU
HuP-T3 M2HvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HSSWlEPTB;MUiuOVg5QCEQvF2= MljCV2FPT0WU
697 NH\FTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF7LkCyNFEh|ryP MnTSV2FPT0WU
MLMA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF7LkC1OVch|ryP M1X4WnNCVkeHUh?=
HCC70 NHyzV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq4[ZFKSzVyPUG5MlQ5QSEQvF2= MkfTV2FPT0WU
A704 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF7LkizNFUh|ryP MYXTRW5ITVJ?
D-283MED M{DJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\UT5JQUUN3ME2yNE42OzN7IN88US=> NIm2SWpUSU6JRWK=
U031 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnlcWJKSzVyPUKxMlE1QDlizszN MmG5V2FPT0WU
HSC-3 NUOxWlR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK1TWM2OD1{MT6xPFM2KM7:TR?= MX\TRW5ITVJ?
JVM-3 M{\CfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\IfpRKSzVyPUKyMlUxPiEQvF2= M2jEfXNCVkeHUh?=
Mewo M2TDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[xc2lEPTB;MkKuOVA4OyEQvF2= NU\vUWVIW0GQR1XS
YH-13 M3vpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnDTWM2OD1{Mj61NVI{KM7:TR?= NV7aPJlMW0GQR1XS
LB1047-RCC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ{LkW4O|kh|ryP NVTSc3RGW0GQR1XS
HCC2157 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[2UmlEPTB;MkKuPFA2PCEQvF2= NXqyUFd3W0GQR1XS
SNU-449 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjtVIN2UUN3ME2yNk45PzR6IN88US=> MWTTRW5ITVJ?
Ramos-2G6-4C10 NHHKTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3LfmJKSzVyPUKyMlk3KM7:TR?= NEHxVWZUSU6JRWK=
CHL-1 NFrzW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TZVWlEPTB;MkOuO|I6OiEQvF2= NUS0dVRmW0GQR1XS
SK-MEL-30 M3nIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;lbm1KSzVyPUK0MlQ3PjJizszN MoHMV2FPT0WU
PANC-08-13 M2XuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP0TWM2OD1{NT6wPVM5KM7:TR?= NE\nU4FUSU6JRWK=
QIMR-WIL NUXFfGpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TKfWlEPTB;MkWuNVg2QCEQvF2= MV7TRW5ITVJ?
BFTC-905 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jo[WlEPTB;MkWuOVk1PCEQvF2= NVPiVodrW0GQR1XS
GI-1 M2G2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr3NXhKSzVyPUK1MlcxPTVizszN M1TuZ3NCVkeHUh?=
MDA-MB-415 M4Thb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln2TWM2OD1{Nj61NFM{KM7:TR?= M3S0SXNCVkeHUh?=
GT3TKB M2i3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWxTWM2OD1{Nj61N|QzKM7:TR?= NYr1TJJOW0GQR1XS
DEL NEnFXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ4LkizOVYh|ryP MUDTRW5ITVJ?
KOSC-2 M3K2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XpeWlEPTB;Mk[uPVA4PSEQvF2= MnrnV2FPT0WU
RVH-421 NYLxTHV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ5LkK5NlEh|ryP MV7TRW5ITVJ?
EW-13 NFTLPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3WmRKSzVyPUK3MlQ{ODhizszN M{\xOXNCVkeHUh?=
639-V NXLLSGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK4c4J2UUN3ME2yO{42OTF7IN88US=> MYHTRW5ITVJ?
A2780 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknjTWM2OD1{Nz62OFEh|ryP NWDpWmt6W0GQR1XS
SW982 NWLoTFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LyXWlEPTB;MkeuPVA2OiEQvF2= NHPIbVVUSU6JRWK=
SW1710 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLFRXRKSzVyPUK4MlA6QDFizszN MXrTRW5ITVJ?
HCC1569 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LYd2lEPTB;MkiuOFg6PyEQvF2= NWXvZoFuW0GQR1XS
MV-4-11 M3\SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ6LkW3N|Uh|ryP MYjTRW5ITVJ?
BHT-101 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljoTWM2OD1{OD62OVczKM7:TR?= MX3TRW5ITVJ?
Ca9-22 NHjXNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ6LkexOEDPxE1? M1f3e3NCVkeHUh?=
HAL-01 NXvIeZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSzTWM2OD1{OD63OlE2KM7:TR?= MVXTRW5ITVJ?
D-263MG M1zJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHrRpRCUUN3ME2yPU4{PDRizszN MV3TRW5ITVJ?
NEC8 NYPBbZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ7LkW1OFgh|ryP M{fhSHNCVkeHUh?=
EKVX MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ZUYRKSzVyPUOxMlU5PDdizszN NX20eGp3W0GQR1XS
EM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW0OWpYUUN3ME2zNU43OzB2IN88US=> MYHTRW5ITVJ?
MFM-223 NHq4bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXm[JlKSzVyPUOxMlgxQThizszN M{fhcnNCVkeHUh?=
SK-PN-DW NIq2S41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknnTWM2OD1|Mj6xOFA3KM7:TR?= Ml;uV2FPT0WU
HuO9 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK2SZRKSzVyPUOyMlUzQDJizszN MkSxV2FPT0WU
MHH-PREB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnIXGtKSzVyPUOyMlYzOzRizszN MlH5V2FPT0WU
OVCAR-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jMTGlEPTB;M{KuPFM3OyEQvF2= M{iyO3NCVkeHUh?=
NCI-H1648 M{nnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PaOWlEPTB;M{KuPFY2OSEQvF2= NXLGZYYzW0GQR1XS
MKN1 NUDVPVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[1N2lEPTB;M{SuNVExOSEQvF2= Mlu3V2FPT0WU
KYSE-450 NHrSe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rLcWlEPTB;M{SuOlQ1PCEQvF2= MXjTRW5ITVJ?
ES8 M2CzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN2Lki5O|Uh|ryP NEjEeotUSU6JRWK=
MS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3VOpNyUUN3ME2zOE46PTV2IN88US=> NIPPW3hUSU6JRWK=
HOP-92 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN3LkmyO|ch|ryP M3raVnNCVkeHUh?=
SKG-IIIa NY\SfWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3sTWM2OD1|Nj6yOVYyKM7:TR?= MXLTRW5ITVJ?
TE-11 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\sd29KSzVyPUO2MlUzPDNizszN M2\OVHNCVkeHUh?=
SK-NEP-1 NEHVXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjhWGpKSzVyPUO3MlY4PDRizszN M{\6VHNCVkeHUh?=
DB NULaRm83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITZXVhKSzVyPUO3MlkyQDVizszN MWDTRW5ITVJ?
IA-LM NFr3NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzmSlhXUUN3ME2zPE4xOjN7IN88US=> MWHTRW5ITVJ?
COLO-829 NYq4d5VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojkTWM2OD1|OD60NVU6KM7:TR?= M1S2OnNCVkeHUh?=
TGBC11TKB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG5TWM2OD1|OT6xOFA5KM7:TR?= MUDTRW5ITVJ?
CAL-51 M4XTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRyLkC2NVIh|ryP MlfRV2FPT0WU
NCI-H2228 NWnTV2xJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LpOWlEPTB;NECuN|Y3OiEQvF2= M4fhZXNCVkeHUh?=
C32 M2W5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\LfJhKSzVyPUSwMlQxOjRizszN NWq3NYxUW0GQR1XS
KU-19-19 M{SxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jucGlEPTB;NECuO|Y5OyEQvF2= MnLDV2FPT0WU
KNS-62 M3LDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLWTWM2OD12MD64N|gyKM7:TR?= M2LTbHNCVkeHUh?=
FADU MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRzLkK1NFIh|ryP MXXTRW5ITVJ?
CAL-33 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR{Lk[3OFkh|ryP M{CzbXNCVkeHUh?=
CHP-134 M1\mWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR{Lki0PVYh|ryP M2HwdnNCVkeHUh?=
HDLM-2 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m1OWlEPTB;NEKuPVA5PCEQvF2= M1[4XXNCVkeHUh?=
NBsusSR MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz3TWM2OD12Mz6wO|I2KM7:TR?= MVLTRW5ITVJ?
SW954 NVTJU|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvOo9KSzVyPUSzMlExPTNizszN MU\TRW5ITVJ?
HCC1806 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3riTWlEPTB;NEOuOFEyKM7:TR?= NU\P[WlXW0GQR1XS
VMRC-RCZ Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT5W4xKSzVyPUSzMlQ2QDZizszN NHraO45USU6JRWK=
A549 NF;DNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW5b2gzUUN3ME20N{46OzFizszN NFHNNnRUSU6JRWK=
NKM-1 M3P2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC4TG1kUUN3ME20N{46PTV6IN88US=> MYPTRW5ITVJ?
DMS-273 NXLNUYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR2Lke1Olch|ryP MWLTRW5ITVJ?
TYK-nu NYnOdpVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fBUGlEPTB;NEWuNVI{PCEQvF2= NWPFcZFyW0GQR1XS
KALS-1 NGXPWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDkTWM2OD12NT6xOFYh|ryP M2LhNHNCVkeHUh?=
A101D M37aT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHTTWM2OD12NT60OFU3KM7:TR?= NYe5UWxqW0GQR1XS
G-361 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\kS4FmUUN3ME20Ok4zOTN6IN88US=> NXz6bGMzW0GQR1XS
KARPAS-299 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKzbVNnUUN3ME20Ok4{PTF4IN88US=> MV3TRW5ITVJ?
RS4-11 M4flfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDCTWM2OD12Nj61OFIh|ryP NV;K[JhDW0GQR1XS
HT-1376 NIWySpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTR4Lke0NlYh|ryP Mle4V2FPT0WU
SK-N-AS NHjHbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR4Lke4NlIh|ryP MojGV2FPT0WU
MG-63 NI\tNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD12Nj65NFM3KM7:TR?= NXXzT|N5W0GQR1XS
EPLC-272H NFnGeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Gw[GlEPTB;NE[uPVUxOyEQvF2= NV20UVZnW0GQR1XS
BALL-1 NX;QTWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OycGlEPTB;NEeuPFMzKM7:TR?= NF6wTHBUSU6JRWK=
LCLC-97TM1 M1rMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[5VGlEPTB;NEiuNlAzKM7:TR?= NFTxWnZUSU6JRWK=
HO-1-N-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR6Lkm2O|Yh|ryP NYPVXWg{W0GQR1XS
MFE-280 M{juRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKxdJBKSzVyPUS5MlQ3OTdizszN NVr2S3Y6W0GQR1XS
NCI-H526 NHXOco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjoeXB{UUN3ME20PU45OTZ|IN88US=> MXLTRW5ITVJ?
D-566MG M3\ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lq[GlEPTB;NEmuPVA6PiEQvF2= Mkf4V2FPT0WU
BB30-HNC NFP2N5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13FcmlEPTB;NEmuPVQ6QCEQvF2= NG[weJpUSU6JRWK=
SK-N-DZ MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi4XWZKSzVyPUWwMlA1QDFizszN MmX6V2FPT0WU
HepG2  NGDsfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jUdlExyqEQvF2= M{LnO|I1KGh? M3nTRoJtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> MmTFNlU2OjdzMkO=
HepG2  NWHKOJJwTnWwY4Tpc44hSXO|YYm= NWDWSmxyOTEEoN88US=> MYWyOEBp MofId5VxeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9veyCxZjDBWG0hd25iU3XyNVk5OSxiQ3jrNUBwdiCVZYKzOFUtKEOqa{Kgc44hXGi{NkisJIFv\CCFZHuyJI9vKFS7ckG1JIlv\HWlZXSgZpkhW0NvSVnJNy=> NXq0eoR2OjV3MkexNlM>
KATO III  NGrUZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33mNFIvPS93L{euOUDPxE1? NIDzZ4ZFVVOR NIHjRZdmdmijbnPld{B1cGVidH;4bYNqfHlib3[gc4xieGG{aXK= MmO3NlQ5PDF5MUi=
hTCEpi NYfmVZFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qw[VExKM7:TR?= MnvUSG1UVw>? M{nHR5Bz\X[nboTzJJRp\SCleYTvdIF1cGmlIHXm[oVkfCCxZjDIV3YuOQ>? Mm\YNlQ{PzB6M{W=
MCF10A M3rYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexNEDPxE1? MYKyOEBp MXjEUXNQ MYHwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD NYXXbIZLOjRzNUC1PVU>
HL-60  Mn:ySpVv[3Srb36gRZN{[Xl? M1L0XlExKM7:TR?= M4Pre|AvPSCq M1XDfWROW09? Mk\RdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gR4hsOsLi NYDmcVFROjN7M{S0NVE>
MCF-7 NHTL[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH4NU0yODEQvF2= NFPlZnkzPCCq M3LDO2ZDWw>? Mn3VbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MmroNlMyQDV|NEe=
HeLa  NWfkfYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\pPVEuOTByzszN Ml7yNlQhcA>? MVfGRnM> NF:wWoxqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NHjqe4czOzF6NUO0Oy=>
SH-SY5Y M4rycmZ2dmO2aX;uJGF{e2G7 MVOxNOKh|ryPwrC= NIf4OI0zPCCq NFftW4FqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= M{DQcFIzPjJ5Mkm0
IMR-32 M{THdWZ2dmO2aX;uJGF{e2G7 NXPIdXNTOTEEoN88UeKh NELSOFYzPCCq Mn;xbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MY[yNlYzPzJ7NB?=
A549 MW\GeY5kfGmxbjDBd5NigQ>? MWGxNOKh|ryPwrC= NITQ[m4yKGh? M{LxVpN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= MY[yNlU2QTN{MR?=
T47D  MVrGeY5kfGmxbjDBd5NigQ>? M{DYU|IxyqCvTR?= NV;K[FhGOjRiaB?= NY\WWmRzTE2VTx?= NUjrRmlReHKndnXueJMhUVJvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= MlfxNlEyPDR6MEW=
A29 MEF NWHxVXBwTnWwY4Tpc44hSXO|YYm= MUexNOKh|ryPwrC= NVm0WXlkOWh? NITQbWJjdG:la4RCpJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JIF1KFOnckS3N:Kh NHjsUYczODB3M{e4NS=>
MDA-MB-453  M1HYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f0VlUuPDBizszN MnjvO|IhcA>? MVjJR|UxKG:oIEGwJO69VQ>? MUOyNFA2Ozd6MR?=
PC-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfQ[2E2NTRyIN88US=> Ml:3O|IhcA>? NI\tTmVKSzVyIH;mJFExKM7:TR?= NUXnXpA2OjByNUO3PFE>

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO and 47.5% PEG300
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID